Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

Qui Tam Challenge At 11th Circuit: 4 Takeaways No Photo Available

Dan McKay

An appellate panel weighed the constitutionality of the False Claim Act's whistleblower mechanism. Law360 Healthcare Authority has wha... (more story)

The Most Important Healthcare And Life Science Deals Of 2025 No Photo Available

Yeji Jesse Lee

Attorneys taking stock of 2025 spoke to Law360 about the most important deals of the year, including Pfizer’s high-profile acquisition... (more story)

Bazelon Center Dir. On Disabilities And Medicaid 'Barriers' No Photo Available

Hannah Albarazi

Law360 Healthcare Authority talks to Jennifer Mathis of the Bazelon Center for Mental Health Law about Medicaid, disability law and wh... (more story)